SYDNEY, AUSTRALIA 30 JUNE 2026 QUARTERLY ACTIVIT Y REPORT Cash Position The Company remains well funded with a cash position of $178.3 million at 30 June 2026, providing Clarity with a strong Balance Sheet to continue progressing its products towards commercialisation. The Company...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Becoming a substantial holder
- Data on SAR-bisPSMA to be presented at EANM
- Clarity receives $9.8 million R&D tax incentive refund
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
Later from Clarity Pharmaceuticals
- Ceasing to be a substantial holder
- SECuRE update
- Notification regarding unquoted securities - CU6
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
- Bioshares Biotech Summit Presentation
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals